As a biopharmaceutical innovator specialized in autoimmunity and inflammation diseases, Xiaolu Biomedicine is committed to developing safe and efficient next-generation therapeutics for autoimmune and inflammatory disorders through original innovation. Grounded in cutting-edge immunology research and starting from disease pathogenesis, the company focuses on identifying fundamental target nodes and combinations with the highest therapeutic potential, aiming to develop third-generation immunomodulatory drugs with global First-in-class potential. These therapies not only pursue superior clinical efficacy but also prioritize long-term, stable efficacy maintenance, holding promise to deliver breakthrough solutions for global autoimmune disease patients and striving to achieve world-leading innovation.

Regarding this financing milestone, Professor Yongjun Liu, Founder of Xiaolu Biomedicine, stated: "We extend heartfelt gratitude to all investors for their trust and support. This angel round represents a milestone for Xiaolu Biomedicine, not only injecting ample start-up capital into the R&D of our new-generation autoimmune and inflammatory drugs but also reflecting the capital market’s high recognition of our development strategy—committed to original innovation and deep cultivation in immunotherapy. We will seize this opportunity to accelerate the development of globally competitive innovative pipelines."

Lily Zhang, Founding Managing Partner of TTM Capital and co-lead investor, expressed confidence in Xiaolu Biomedicine’s prospects: "Professor Yongjun Liu’s industrial transformation capability in immunotherapy is remarkable. He has not only made substantial achievements in basic research but also demonstrated a solid biomedical foundation and a R&D methodology oriented toward addressing unmet clinical needs in key industrialization stages of drug development. We particularly value the differentiated development strategy established by Professor Liu’s team in autoimmune diseases—this ability to precisely align frontier science with clinical needs embodies the core edge for Chinese innovative pharmaceutical companies to compete globally. As a strategic partner, TTM Capital will leverage its deep biomedical industry resources to assist Xiaolu Biomedicine in refining global commercial layouts and accelerating innovative pipelines with international patent protection."

Professor Yongjun Liu

Notably, Professor Yongjun Liu is an internationally recognized top immunology expert and the highest-ranking Chinese scientist in multinational pharmaceutical enterprises. During his distinguished academic and industrial career, he has held key positions including Global R&D Head of Sanofi, President of Innovent Bio, Chief Scientific Officer of Baylor Research Institute and Director of Baylor Institute for Immunology Research, Director of the Department of UT MD Anderson Cancer Center, and Founding Director of its Cancer Immunology Research Center. His multiple breakthroughs in basic immunology research and translational medicine will provide solid support for Xiaolu Biomedicine’s innovative development.

Against the backdrop of profound changes in the global biomedical innovation landscape, Chinese innovative pharmaceutical companies are gradually shifting from "followed innovation" to "original innovation." With its world-class scientific team, differentiated R&D strategy, and deep understanding of clinical needs, Xiaolu Biomedicine is poised to make breakthroughs in major autoimmune disease areas, setting new momentum into the high-quality development of China’s biomedical industry. The favor from top investment institutions also signals the capital market’s sustained optimism toward Chinese biomedical innovation.

Who we are

TTM Capital is a professional investment institution focused on early-stage investments in the healthcare sector. The founding and managing team been involved in the medical and biotechnology fields for many years, with a background in medical investments from top domestic funds to full industry chain experience from globally leading multinational pharmaceutical companies.
TTM Capital mainly focuses on high-quality investment opportunities in the fields of biopharmaceuticals, medical devices and in vitro diagnostics driven by cutting-edge technology, focusing on segmented tracks with significant advantages, focusing on the global medical market and the "unmet needs" of patients. Persist in empowering and creating synergistic value for invested companies, jointly promote medical innovation, and create value for society.